Dr Rakesh Popat, Consultant Haematologist
Dr Rakesh Popat
Consultant Haematologist
Dr Rakesh Popat BSc, MBBS, MRCP, FRCPath, PhD
Consultant Haematologist
Dr Rakesh Popat
Consultant Haematologist BSc, MBBS, MRCP, FRCPath, PhD
Dr Popat is a recommended Consultant Haematologist
Areas of expertise
- Blood diseases (clinical haematology)
- Myeloma
- Haemato-oncology
- Blood cancer
- Bone marrow transplant
Recommendations for Dr Popat
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
byMr Sam Singh, Consultant Orthopaedic Foot & Ankle Surgeon
❝Dr Rakesh Popat is a great haematologist. He's very knowledgeable and has a very good bedside manner.❞
byMr Sam Singh, Consultant Orthopaedic Foot & Ankle Surgeon
❝Dr Rakesh Popat is a great haematologist. He's very knowledgeable and has a very good bedside manner.❞
Make an appointment
Address
-
HCA UK at University College Hospital
Grafton Way Building, 1 Grafton Way, London, WC1E 6AG
About Dr Rakesh Popat
GMC number: 4432920
Year qualified: 1997
Place of primary qualification: University of London
Dr Rakesh Popat is a consultant haematologist with specialist expertise in multiple myeloma. His NHS base is at University College Hospital, London, where he leads the Myeloma Clinical Trials Program and serves as the cancer program lead for the NIHR UCLH Clinical Research Facility. Dr Popat has particular experience with novel treatments, including immunotherapies such as CAR-T cell therapy and new antibody approaches.
Dr Popat is the chair of the UK Myeloma Research Alliance and is on the leadership boards of the UK Myeloma Forum and the European Myeloma Network. Additionally, he is the haematology lead for the North Thames Clinical Research Network. He completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute in Boston, USA, as part of this.
Dr Popat's areas of expertise include the diagnosis and treatment of multiple myeloma, stem cell transplants, and a specific interest in new treatments, including immunotherapies. He has been at the forefront of advancing myeloma research and treatment since his appointment, contributing significantly to the field.
Areas of expertise
- Myleloma
- Lymphomas
- Thrombosis and embolism
Professional memberships
Articles by Dr Rakesh Popat
Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (gsk2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (covid‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy.
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (mascot): an exploratory randomised phase 2 trial utilising a modified zelen design
Correction to: corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, dreamm-2 study
Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, dreamm-2 study
Antibody–drug conjugate, gsk2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase i study
How to simplify the evaluation of newly introduced chemotherapeutic interventions in myeloma
